CN112770774A - 提供安全施用抗cd154抗体的方法 - Google Patents

提供安全施用抗cd154抗体的方法 Download PDF

Info

Publication number
CN112770774A
CN112770774A CN201980062755.5A CN201980062755A CN112770774A CN 112770774 A CN112770774 A CN 112770774A CN 201980062755 A CN201980062755 A CN 201980062755A CN 112770774 A CN112770774 A CN 112770774A
Authority
CN
China
Prior art keywords
antibody
antigen
binding fragment
administration
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980062755.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·里格比
D·赖布勒
A·皮安托内
J·雷
N·C·沙宾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CN112770774A publication Critical patent/CN112770774A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201980062755.5A 2018-09-24 2019-09-24 提供安全施用抗cd154抗体的方法 Pending CN112770774A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862735529P 2018-09-24 2018-09-24
US62/735529 2018-09-24
US201962826131P 2019-03-29 2019-03-29
US62/826131 2019-03-29
PCT/US2019/052558 WO2020068723A1 (en) 2018-09-24 2019-09-24 Method of providing safe administration of an anti-cd154 antibody

Publications (1)

Publication Number Publication Date
CN112770774A true CN112770774A (zh) 2021-05-07

Family

ID=69950835

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980062755.5A Pending CN112770774A (zh) 2018-09-24 2019-09-24 提供安全施用抗cd154抗体的方法

Country Status (6)

Country Link
US (1) US20210317220A1 (enExample)
EP (1) EP3856246A4 (enExample)
JP (1) JP2022502380A (enExample)
CN (1) CN112770774A (enExample)
AU (1) AU2019347730A1 (enExample)
WO (1) WO2020068723A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3185091A1 (en) * 2020-07-08 2022-01-13 Yuan Cheng Stabilized formulations containing anti-ctla-4 antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101809036A (zh) * 2007-09-24 2010-08-18 霍夫曼-拉罗奇有限公司 奥瑞珠单抗(2h7)的固定的单次注射剂量
CN108135969A (zh) * 2015-07-14 2018-06-08 里姆蒙埃克斯特股份有限公司 具有改善的结合、功能和安全性特征的抗cd154抗体及其在人免疫治疗中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101540823B1 (ko) * 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
US9028826B2 (en) * 2011-04-04 2015-05-12 The Trustees Of Dartmouth College Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
KR102434073B1 (ko) * 2011-10-11 2022-08-18 비엘라 바이오, 인크. Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
GB201501613D0 (en) * 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
MY188405A (en) * 2015-08-05 2021-12-08 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101809036A (zh) * 2007-09-24 2010-08-18 霍夫曼-拉罗奇有限公司 奥瑞珠单抗(2h7)的固定的单次注射剂量
CN108135969A (zh) * 2015-07-14 2018-06-08 里姆蒙埃克斯特股份有限公司 具有改善的结合、功能和安全性特征的抗cd154抗体及其在人免疫治疗中的用途

Also Published As

Publication number Publication date
AU2019347730A1 (en) 2021-03-25
EP3856246A4 (en) 2022-07-20
EP3856246A1 (en) 2021-08-04
WO2020068723A1 (en) 2020-04-02
JP2022502380A (ja) 2022-01-11
US20210317220A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
JP7587858B2 (ja) ヒトｃｄ１３７に結合するアゴニスト性抗体およびその使用
JP7587629B2 (ja) アンタゴニストｃｄ４０モノクローナル抗体およびその使用
TWI857389B (zh) 治療發炎症狀的方法
US10851158B2 (en) Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof
US20250019451A1 (en) Anti-ccr8 antibodies and uses thereof
JP2019506403A (ja) がんを処置するためのｏｘ４０アゴニストおよび４−１ｂｂアゴニストモノクローナル抗体の組み合わせ
US20130315913A1 (en) Anti-light antibody therapy for inflammatory bowel disease
CN113784985A (zh) T1dm和胰岛炎的治疗中使用的抗cd40抗体
KR20190027375A (ko) 항체 제형
US11851497B2 (en) CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
JP2024097985A (ja) 抗ｇｉｔｒ抗体およびその使用
Burge et al. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study
US20080254030A1 (en) Use of Baff to Treat Th2-Mediated Conditions
US20210317220A1 (en) Method of providing safe administration of an anti-cd154 antibody
KR20220012918A (ko) 항-cd40 항체의 안전한 투여를 제공하는 방법
HK40050403A (en) Method of providing safe administration of an anti-cd154 antibody
KR20210131312A (ko) 인간 cd137에 결합하는 항체의 제제 및 이의 용도
WO2019199896A9 (en) Agonist antibodies against human cd137 in cancer that express mhc i
CN119421723A (zh) 用双特异性抗PSMA x抗CD3抗体单独或与抗PD-1抗体组合治疗转移性去势抵抗性前列腺癌的方法
WO2023004420A1 (en) Dual-blockade of il-4 signaling and immune checkpoint proteins for treating cancer
JP2013199492A (ja) Ｆｄｆ０３抗体およびそれの使用
WO2026096939A1 (en) Cancer treatment methods
EA043630B1 (ru) Способы лечения воспалительных состояний

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40050403

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210507